VALBONNE, France--(BUSINESS WIRE)--Regulatory News:
TxCell SA (Paris:TXCL) (FR0010127662 – TXCL), a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, today announces that two posters with new CAR-Treg related data will be presented at the 25th Anniversary Congress of the European Society of Gene & Cell Therapy (ESGCT) to be held on October 17-20, 2017 in Berlin, Germany.
- Combination of transduction enhancers with Ecotropic-MLV pseudotyped lentiviral vectors enables highly efficient transfer of chimeric antigen receptors into murine T effector and T regulatory lymphocytes, Fenard D (presenting author), David M, Abel T, Marchetti I, Asnagli H, Zhou L and Meyer F, Poster session 2, October 19, 2017, 5.40-8pm.
In this poster, David Fenard, PhD, Director Gene Transfer at TxCell, will present TxCell’s strategy to genetically modify murine T cells – both effector T cells (Teffs) and regulatory T cell (Tregs) – with a lentiviral vector.
- Designing the next generation of chimeric Antigen receptors for Regulatory T cell therapy through in silico modeling-guided single chain Fv engineering, Abel T (presenting author), Schneider IC, Beghelli S, Labbal F, David M, Zhou M and Meyer F, Poster session 2, October 19, 2017, 5.40-8pm.
In this poster, Tobias Abel, PhD, Manager CAR Engineering at TxCell, will present the design of TxCell’s next-generation CARs for regulatory T cell therapy, using in silico modeling-guided single-chain variable fragment (scFv) engineering. This follows the oral presentation and poster presented at the CAR-TCR Summit by Li Zhou, PhD, Vice President Cell Engineering at TxCell, in September 2017.
Abstracts will be made available on October 17, 2017 both on TxCell’s website www.txcell.com in the Technology/Publications & Abstracts section as well as on the conference website www.esgct.eu/congress.aspx.
About TxCell – www.txcell.com
TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need. TxCell is targeting a range of autoimmune diseases (both T-cell and B-cell-mediated) including multiple sclerosis, lupus nephritis and bullous pemphigoid, as well as transplant rejection.
TxCell’s cellular immunotherapies are based on regulatory T lymphocytes (Tregs). Tregs are a T cell population discovered in the nineties for which anti-inflammatory properties have been demonstrated. Contrary to conventional approaches based on non-specific polyclonal Tregs, TxCell is exclusively developing engineered antigen-specific Tregs, where the antigen specificity is brought by a Chimeric Antigen Receptor (CAR) (CAR-Treg cells).
Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 46 employees.
Next TxCell events
Scientific and medical conferences
|Oct 9-11||Final conference on the COST ‘A FACTT’ project||
|Oct 17-20||ESGCT 2017 (European Society of Gene & Cell Therapy)||Berlin (DE)|
Financial and business conferences
|Oct 4-5||Large & Midcap Event Paris||Paris (FR)|
|Oct 4-5||Cell & Gene Meeting on the Mesa||La Jolla (US)|
|Nov 6-9||BIO-Europe||Berlin (DE)|
|Nov 9||5th Annual European Advanced Therapies Investor Day||London (UK)|
|Nov 14||Inv€$tival Showcase||London (UK)|
|Nov 15-16||Jefferies 2017 Global Healthcare Conference||London (UK)|
|Nov 23-24||Actionaria||Paris (FR)|
This press release contains certain forward-looking statements relating to the business of TxCell, which shall not be considered per se as historical facts, including TxCell’s ability to develop, market, commercialize and achieve market acceptance for specific products, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements, needs for additional financing. In addition, even if the actual results or development of TxCell are consistent with the forward-looking statements contained in this press release, those results or developments of TxCell may not be indicative of their in the future.
In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. Although the management of TxCell believes that these forward-looking statements are reasonably made, they are based largely on the current expectations of TxCell as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of TxCell could be affected by, among other things, uncertainties involved in the development of the Company’s products, which may not succeed, or in the delivery of TxCell’s products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affects TxCell capacity to commercialize the products it develops, as well as, any other risk and uncertainties developed or identified in any public documents filed by TxCell with the AMF, included those listed in chapter 4 “Risk factors” of the 2016 document de référence (registration document) approved by the AMF on April 26, 2017 under number R.17-024. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Notwithstanding the compliance with article 223-1 of the General Regulation of the AMF (the information disclosed must be “accurate, precise and fairly presented”), TxCell is providing the information in these materials as of this press release, and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.